Sorafenib, a potent multikinase inhibitor, induces apoptosis of human acute myeloid leukemia (AML) cells through downregulating Mcl-1 and enhancing binding of Bim to Bcl-2 and Bcl-xL [611]. Here, BCL2L11 is linked to acute myeloid leukemia.